AbbVie
ABBV
$162.73
Share price
-0.65%
Change (1 day)
10.36%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Earnings for AbbVie (ABBV)
Earnings in 2023 (TTM): $6.25 B
According to AbbVie's latest financial reports the company's current earnings (TTM) are $6.25 B. In 2022 the company made an earning of $13.47 B an increase over its 2021 earnings that were of $12.98 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for AbbVie from 2011 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2023 (TTM)  | $6.25 B | -53.62% |
| 2022 | $13.47 B | 3.76% |
| 2021 | $12.98 B | 282.25% |
| 2020 | $3.39 B | -59.67% |
| 2019 | $8.42 B | 62.13% |
| 2018 | $5.19 B | -32.74% |
| 2017 | $7.72 B | -1.99% |
| 2016 | $7.88 B | 18.65% |
| 2015 | $6.64 B | 180.5% |
| 2014 | $2.36 B | -55.57% |
| 2013 | $5.33 B | -6.86% |
| 2012 | $5.72 B | 56.05% |
| 2011 | $3.66 B |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $3.26 B | -47.73% | 🇺🇸 USA |
 Eli Lilly LLY | $7.56 B | 20.98% | 🇺🇸 USA |
 Amgen AMGN | $7.85 B | 25.68% | 🇺🇸 USA |
 Biogen BIIB | $1.32 B | -78.83% | 🇺🇸 USA |
 Gilead Sciences GILD | $6.85 B | 9.74% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | -$5.85 B | -193.54% | 🇺🇸 USA |
 AstraZeneca AZN | $9.08 B | 45.30% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $6.88 B | 10.16% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $0.47 B | -92.40% | 🇺🇸 USA |